🇺🇸 VP-16 in United States

1,364 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 1,364

Most-reported reactions

1. Febrile Neutropenia — 214 reports (15.69%)
2. Pyrexia — 212 reports (15.54%)
3. Nausea — 146 reports (10.7%)
4. Neutropenia — 144 reports (10.56%)
5. Vomiting — 142 reports (10.41%)
6. Hypotension — 124 reports (9.09%)
7. Diarrhoea — 105 reports (7.7%)
8. Fatigue — 97 reports (7.11%)
9. Neutrophil Count Decreased — 91 reports (6.67%)
10. Platelet Count Decreased — 89 reports (6.52%)

Source database →

Frequently asked questions

Is VP-16 approved in United States?

VP-16 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for VP-16 in United States?

PETHEMA Foundation is the originator. The local marketing authorisation holder may differ — check the official source linked above.